Home / Resources / Supplier qualification

Supplier qualification · 4 min read

Shared Audits: When They Work and When They Do Not

Supplier audits are an important part of pharmaceutical quality management. However, auditing every supplier independently can require significant time, resources, and coordination. In some circumstances, organizations may consider using an existing audit report or a report shared by another customer to support their supplier qualification activities.

While shared audits can improve efficiency, an existing audit report is not automatically suitable for every supplier qualification decision. Its acceptability depends on the audit scope, the quality of the evidence, the age of the report, the findings identified, and the purpose for which it will be used.

This article explains how pharmaceutical organizations can evaluate shared audit reports and determine when additional assessment may be necessary.

1. What Is a Shared Audit?

A shared audit is an audit whose results or report are made available to more than one organization. This may occur through customer collaboration, an audit-sharing arrangement, or access to an existing third-party audit report.

Shared audits can reduce duplication when several customers rely on the same supplier. However, each organization remains responsible for determining whether the available evidence is adequate for its own quality system and supplier qualification requirements.

2. When Can a Shared Audit Be Useful?

A shared audit may be useful when:

  • The report covers the correct manufacturing site and relevant activities.
  • The audit criteria are appropriate for the supplier's products and operations.
  • The report contains sufficient objective evidence and clearly documented findings.
  • The audit is recent enough to reflect the supplier's current operations and risk profile.
  • Significant findings, corrective actions, and outstanding issues can be evaluated.
  • The report is accessible, authentic, and permitted to be used for the intended purpose.

For example, if several pharmaceutical companies purchase an API from the same manufacturing site, an appropriate existing audit report may provide useful evidence about the site's quality systems and manufacturing controls.

The receiving organization should still evaluate whether the audit adequately addresses the risks associated with its particular API, supply chain, and intended use.

3. Six Factors to Assess Before Accepting a Shared Audit

Audit scope

Confirm the site, products, manufacturing processes, laboratories, storage facilities, and quality systems covered by the audit. An audit of warehousing alone may not be sufficient to evaluate a site's API manufacturing operations.

Audit age

Review the audit date and determine whether significant changes have occurred since the assessment. Changes in ownership, manufacturing processes, facilities, equipment, management, or regulatory status may affect the report's continuing relevance.

There is no single audit age that automatically makes every report acceptable or unacceptable. The decision should be justified according to risk, applicable requirements, and internal procedures.

Coverage and completeness

Check whether the report provides adequate coverage of the relevant GMP requirements and critical operations. Identify exclusions, limitations, or areas that were not assessed.

Evidence and findings

A credible report should explain the observations made, the evidence reviewed, the requirements involved, and the significance of identified deficiencies. Broad statements such as “GMP compliant” without supporting detail may provide insufficient assurance.

CAPA and follow-up

Review the status of corrective and preventive actions (CAPAs), including root-cause investigations, implementation evidence, and effectiveness checks where appropriate. Unresolved significant findings may require further investigation or follow-up.

Intended use and access

Determine whether the report is suitable for the specific supplier qualification or monitoring decision. Consider confidentiality restrictions, authorization to share the report, report authenticity, and whether enough information is available for a meaningful review.

4. When Is a Shared Audit Not Enough?

An existing report may not provide adequate assurance when:

  • The audit scope does not cover the relevant product or manufacturing activities.
  • The report is outdated in relation to the supplier's current risk profile.
  • Significant findings remain unresolved or their status is unclear.
  • Data integrity concerns or critical process weaknesses require further assessment.
  • The report contains substantial exclusions or insufficient supporting evidence.
  • A specific customer, product, or regulatory requirement calls for additional assessment.

In such cases, the organization may need further documentation, a focused follow-up assessment, or a separate audit.

5. A Practical Review Process

A structured review helps make the decision consistent and traceable.

  • Verify the report: Confirm the supplier, site, audit date, scope, and report authenticity.
  • Assess relevance: Compare the audit coverage with the products, activities, and risks involved.
  • Evaluate findings: Review their significance, supporting evidence, and CAPA status.
  • Identify gaps: Document missing information, exclusions, and areas requiring clarification.
  • Make a justified decision: Accept the report as supporting evidence, request additional information, or arrange further assessment.
  • Document the rationale: Record the decision and any conditions or follow-up actions within the quality system.

Conclusion

Shared audits can be a practical way to reduce duplicated effort and make supplier oversight more efficient. Their value, however, depends on the relevance, completeness, credibility, and continuing suitability of the audit evidence.

The key question is not simply whether an audit report exists, but whether it provides adequate evidence for the quality decision being made.

PharmaTrak focuses on independent, evidence-based GxP audits that help pharmaceutical organizations assess supplier compliance, identify gaps, and support informed quality decisions.

Regulatory note: This article is for general educational purposes. The use of shared audit reports should be evaluated against applicable regulatory requirements, contractual arrangements, and the organization's approved quality procedures.

Discuss your audit requirements

Independent, evidence-based GxP audits from PharmaTrak.

Request an Audit